Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H29NO11 |
| Molecular Weight | 543.5193 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@H](N)[C@H](O)[C@H](C)O1)O[C@H]2C[C@@](O)(CC3=C(O)C4=C(C(=O)C5=C(OC)C=CC=C5C4=O)C(O)=C23)C(=O)CO
InChI
InChIKey=AOJJSUZBOXZQNB-TZSSRYMLSA-N
InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
| Molecular Formula | C27H29NO11 |
| Molecular Weight | 543.5193 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28846045 | https://clinicaltrials.gov/ct2/show/NCT02049905 | https://www.ncbi.nlm.nih.gov/pubmed/26378637 | https://clinicaltrials.gov/ct2/show/NCT02014844 | https://www.ncbi.nlm.nih.gov/pubmed/25312684 | https://clinicaltrials.gov/ct2/show/NCT02200757
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28846045 | https://clinicaltrials.gov/ct2/show/NCT02049905 | https://www.ncbi.nlm.nih.gov/pubmed/26378637 | https://clinicaltrials.gov/ct2/show/NCT02014844 | https://www.ncbi.nlm.nih.gov/pubmed/25312684 | https://clinicaltrials.gov/ct2/show/NCT02200757
Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-cancer agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.
Originator
Sources: https://books.google.ru/books?id=_J2ti4EkYpkC&pg=PA1397&lpg=PA1397&dq=DOXORUBICIN retrieved from Pharmaceutical Manufacturing Encyclopedia William Andrew Publishing, p.1397https://encrypted.google.com/patents/WO2012167255A1
Curator's Comment: Introduced as Adriblastina by Farmitalia, Italy, in 1971
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094255 |
2.67 µM [IC50] | ||
Target ID: CHEMBL3253 |
|||
Target ID: CHEMBL1806 Sources: http://www.drugbank.ca/drugs/DB00997 |
|||
Target ID: CHEMBL2094255 |
2.67 µM [IC50] | ||
Target ID: CHEMBL614517 |
200.0 nM [IC50] | ||
Target ID: CHEMBL395 |
24.68 µM [IC50] | ||
Target ID: CHEMBL613895 |
0.074 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | DOXIL Approved UseIndicated for:
Ovarian cancer
After failure of platinum-based chemotherapy.
AIDS-related Kaposi’s Sarcoma
After failure of prior systemic chemotherapy or intolerance to such therapy.
Multiple Myeloma Launch Date1995 |
|||
| Primary | DOXIL Approved UseIndicated for:
Ovarian cancer
After failure of platinum-based chemotherapy.
AIDS-related Kaposi’s Sarcoma
After failure of prior systemic chemotherapy or intolerance to such therapy.
Multiple Myeloma Launch Date1995 |
|||
| Primary | DOXIL Approved UseIndicated for:
Ovarian cancer
After failure of platinum-based chemotherapy.
AIDS-related Kaposi’s Sarcoma
After failure of prior systemic chemotherapy or intolerance to such therapy.
Multiple Myeloma Launch Date1995 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26115930 |
60 mg/m² 1 times / day steady-state, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
DOXORUBICIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7.4 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26115930 |
60 mg/m² 1 times / day steady-state, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
DOXORUBICIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
34.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26115930 |
60 mg/m² 1 times / day steady-state, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
DOXORUBICIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
25% |
DOXORUBICIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
150 mg/m2 1 times / day multiple, intravenous Overdose Dose: 150 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / day Sources: |
unhealthy, 17 years n = 1 Health Status: unhealthy Age Group: 17 years Sex: F Population Size: 1 Sources: |
Other AEs: Mucositis, Chills... Other AEs: Mucositis (severe, 1 patient) Sources: Chills (1 patient) Pyrexia (1 patient) |
300 mg/m2 single, intravenous Overdose Dose: 300 mg/m2 Route: intravenous Route: single Dose: 300 mg/m2 Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: acute lymphoblastic leukemia Age Group: 58 years Sex: M Population Size: 1 Sources: |
Other AEs: Sinus tachycardia, Neutropenia... Other AEs: Sinus tachycardia (1 patient) Sources: Neutropenia (grade 4, 1 patient) Thrombocytopenia (1 patient) Mucositis (severe, 1 patient) Sepsis (severe, 1 patient) |
60 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 60 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Tissue injury... Other AEs: Acute myeloid leukaemia, Myelodysplastic syndrome... AEs leading to discontinuation/dose reduction: Tissue injury (severe) Other AEs:Acute myeloid leukaemia Sources: Myelodysplastic syndrome Myelosuppression (severe) |
300 mg/m2 1 times / 3 weeks multiple, intravenous (total) Dose: 300 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 300 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Sources: |
Other AEs: Cardiomyopathy... Other AEs: Cardiomyopathy Sources: |
450 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 450 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 450 mg/m2, 1 times / 3 weeks Sources: Page: p.574 |
unhealthy, ADULT n = 2 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 2 Sources: Page: p.574 |
DLT: Neutropenia, Febrile neutropenia... Disc. AE: Anemia, Neutropenia... Dose limiting toxicities: Neutropenia (grade 4, 50%) AEs leading toFebrile neutropenia (grade 3, 50%) discontinuation/dose reduction: Anemia (grade 3, 50%) Sources: Page: p.574Neutropenia (grade 3, 50%) |
350 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 350 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 350 mg/m2, 1 times / 3 weeks Sources: Page: p.574 |
unhealthy, ADULT n = 18 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: Page: p.574 |
DLT: Dehydration, Neutropenia... Disc. AE: Septic shock, Anemia... Dose limiting toxicities: Dehydration (5.6%) AEs leading toNeutropenia (5.6%) Sepsis (5.6%) discontinuation/dose reduction: Septic shock (grade 5, 5.6%) Sources: Page: p.574Anemia (grade 3, 5.6%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Chills | 1 patient | 150 mg/m2 1 times / day multiple, intravenous Overdose Dose: 150 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / day Sources: |
unhealthy, 17 years n = 1 Health Status: unhealthy Age Group: 17 years Sex: F Population Size: 1 Sources: |
| Pyrexia | 1 patient | 150 mg/m2 1 times / day multiple, intravenous Overdose Dose: 150 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / day Sources: |
unhealthy, 17 years n = 1 Health Status: unhealthy Age Group: 17 years Sex: F Population Size: 1 Sources: |
| Mucositis | severe, 1 patient | 150 mg/m2 1 times / day multiple, intravenous Overdose Dose: 150 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / day Sources: |
unhealthy, 17 years n = 1 Health Status: unhealthy Age Group: 17 years Sex: F Population Size: 1 Sources: |
| Sinus tachycardia | 1 patient | 300 mg/m2 single, intravenous Overdose Dose: 300 mg/m2 Route: intravenous Route: single Dose: 300 mg/m2 Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: acute lymphoblastic leukemia Age Group: 58 years Sex: M Population Size: 1 Sources: |
| Thrombocytopenia | 1 patient | 300 mg/m2 single, intravenous Overdose Dose: 300 mg/m2 Route: intravenous Route: single Dose: 300 mg/m2 Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: acute lymphoblastic leukemia Age Group: 58 years Sex: M Population Size: 1 Sources: |
| Neutropenia | grade 4, 1 patient | 300 mg/m2 single, intravenous Overdose Dose: 300 mg/m2 Route: intravenous Route: single Dose: 300 mg/m2 Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: acute lymphoblastic leukemia Age Group: 58 years Sex: M Population Size: 1 Sources: |
| Mucositis | severe, 1 patient | 300 mg/m2 single, intravenous Overdose Dose: 300 mg/m2 Route: intravenous Route: single Dose: 300 mg/m2 Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: acute lymphoblastic leukemia Age Group: 58 years Sex: M Population Size: 1 Sources: |
| Sepsis | severe, 1 patient | 300 mg/m2 single, intravenous Overdose Dose: 300 mg/m2 Route: intravenous Route: single Dose: 300 mg/m2 Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: acute lymphoblastic leukemia Age Group: 58 years Sex: M Population Size: 1 Sources: |
| Acute myeloid leukaemia | 60 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 60 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Sources: |
|
| Myelodysplastic syndrome | 60 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 60 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Sources: |
|
| Myelosuppression | severe | 60 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 60 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Sources: |
| Tissue injury | severe Disc. AE |
60 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 60 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 60 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Sources: |
| Cardiomyopathy | 300 mg/m2 1 times / 3 weeks multiple, intravenous (total) Dose: 300 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 300 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Sources: |
|
| Febrile neutropenia | grade 3, 50% DLT |
450 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 450 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 450 mg/m2, 1 times / 3 weeks Sources: Page: p.574 |
unhealthy, ADULT n = 2 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 2 Sources: Page: p.574 |
| Anemia | grade 3, 50% Disc. AE |
450 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 450 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 450 mg/m2, 1 times / 3 weeks Sources: Page: p.574 |
unhealthy, ADULT n = 2 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 2 Sources: Page: p.574 |
| Neutropenia | grade 3, 50% Disc. AE |
450 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 450 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 450 mg/m2, 1 times / 3 weeks Sources: Page: p.574 |
unhealthy, ADULT n = 2 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 2 Sources: Page: p.574 |
| Neutropenia | grade 4, 50% DLT |
450 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 450 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 450 mg/m2, 1 times / 3 weeks Sources: Page: p.574 |
unhealthy, ADULT n = 2 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 2 Sources: Page: p.574 |
| Dehydration | 5.6% DLT |
350 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 350 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 350 mg/m2, 1 times / 3 weeks Sources: Page: p.574 |
unhealthy, ADULT n = 18 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: Page: p.574 |
| Neutropenia | 5.6% DLT |
350 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 350 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 350 mg/m2, 1 times / 3 weeks Sources: Page: p.574 |
unhealthy, ADULT n = 18 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: Page: p.574 |
| Sepsis | 5.6% DLT |
350 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 350 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 350 mg/m2, 1 times / 3 weeks Sources: Page: p.574 |
unhealthy, ADULT n = 18 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: Page: p.574 |
| Anemia | grade 3, 5.6% Disc. AE |
350 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 350 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 350 mg/m2, 1 times / 3 weeks Sources: Page: p.574 |
unhealthy, ADULT n = 18 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: Page: p.574 |
| Septic shock | grade 5, 5.6% Disc. AE |
350 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 350 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 350 mg/m2, 1 times / 3 weeks Sources: Page: p.574 |
unhealthy, ADULT n = 18 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: Page: p.574 |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| weak | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes [Km 5.2 uM] | ||||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
| yes | ||||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
Page: - |
yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Experimental animal models of adriamycin cardiotoxicity. | 1979 May |
|
| Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. | 1999 Apr |
|
| Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis. | 1999 Apr-Jun |
|
| Sodium bicarbonate treatment reduces renal injury, renal production of transforming growth factor-beta, and urinary transforming growth factor-beta excretion in rats with doxorubicin-induced nephropathy. | 1999 Aug |
|
| Doxorubicin cardiotoxicity: growing importance. | 1999 Jul |
|
| Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma. | 1999 Jul |
|
| Delayed methotrexate clearance in a patient with sickle cell anemia and osteosarcoma. | 1999 Mar-Apr |
|
| Exposure to hydrocarbons and renal disease: an experimental animal model. | 1999 May-Jul |
|
| Primary desmoplastic small cell tumor of soft tissues and bone of the hand. | 1999 Nov |
|
| Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. | 1999 Oct |
|
| Renal protective effects of blocking the intrarenal renin-angiotensin system. | 1999 Sep |
|
| Doxorubicin-induced late cardiotoxicity: delayed impairment of Ca2+-handling mechanisms in the sarcoplasmic reticulum in the rat. | 2000 Apr |
|
| The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. | 2000 Aug |
|
| The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats. | 2000 Aug |
|
| Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy. | 2000 Dec 1 |
|
| Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. | 2000 Dec 15 |
|
| Oxidative stress involvement in chemically induced differentiation of K562 cells. | 2000 Jan 1 |
|
| Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. | 2000 Jan 4 |
|
| Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. | 2000 Jan 7-21 |
|
| Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. | 2000 Jul 1 |
|
| Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies. | 2000 May |
|
| Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma. | 2000 May-Jun |
|
| Mobilization of hematopoietic progenitor cells with a combination of docetaxel, adriamycin, 5-fluorouracil and filgrastim in breast cancer patients. | 2001 Jan |
|
| Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. | 2001 Jan 1 |
|
| Characterization of adriamycin-induced G2 arrest and its abrogation by caffeine in FL-amnion cells with or without p53. | 2001 Jan 1 |
|
| Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells. | 2001 Jan 26 |
Patents
Sample Use Guides
When used in combination with other chemotherapy drugs, the most commonly used dosage of doxorubicin is 40 to 60 mg/m2 IV every 21 to 28 days. Alternatively, 60 to 75 mg/m2 IV once every 21 days.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:21:26 GMT 2023
by
admin
on
Fri Dec 15 17:21:26 GMT 2023
|
| Record UNII |
80168379AG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000007530
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
199904
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
276009
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
553116
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
820821
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
NDF-RT |
N0000007530
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
248107
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
469215
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
844921
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
808521
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
WHO-VATC |
QL01DB01
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
NDF-RT |
N0000000176
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
NDF-RT |
N0000007530
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
139800
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
286109
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
NCI_THESAURUS |
C67502
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
NDF-RT |
N0000175414
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
117398
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
LIVERTOX |
NBK548622
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/15/1513
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
||
|
WHO-ATC |
L01DB01
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID8021480
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
3639
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL53463
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
SUB35582
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
7069
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
960
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
Doxorubicin
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
23214-92-8
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
245-495-6
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
123127
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
D004317
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
80168379AG
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
759155
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
80168379AG
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
DB00997
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
100000085265
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
28748
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
3005
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
DOXORUBICIN
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
C456
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
64816
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
m4757
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB06391MIG
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
31703
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY | |||
|
3070
Created by
admin on Fri Dec 15 17:21:26 GMT 2023 , Edited by admin on Fri Dec 15 17:21:26 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
|
TRANSPORTER -> SUBSTRATE |
Dogs homozygous or heterozygous for the ABCB1-1Δ mutation are significantly more likely than normal dogs to develop haematological and gastrointestinal toxicity.
|
||
|
TARGET -> INHIBITOR |
BINDING
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
TRANSPORTER -> SUBSTRATE |
Responsible for the resistance to doxorubicin of a subset of malignant melanomas.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
METABOLITE -> PARENT |
MAJOR
|
||
|
|
PRODRUG -> METABOLITE ACTIVE |
Reacts with the Cys-34 of albumin gets transported to tumor microenvironment and released in acidic environment.
|
||
|
METABOLITE -> PARENT | |||
|
|
METABOLITE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> IMPURITY |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
|
PARENT -> IMPURITY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
|
|||